Cargando…
PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
Breast cancer and gynecological tumors seriously endanger women’s physical and mental health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and radiotherapy, the prognosis and overall survival of cancer patients have improved compared to earlier, but the manag...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455597/ https://www.ncbi.nlm.nih.gov/pubmed/36091750 http://dx.doi.org/10.3389/fphar.2022.967633 |
_version_ | 1784785614084767744 |
---|---|
author | Wang, Nannan Yang, Yan Jin, Dongdong Zhang, Zhenan Shen, Ke Yang, Jing Chen, Huanhuan Zhao, Xinyue Yang, Li Lu, Huaiwu |
author_facet | Wang, Nannan Yang, Yan Jin, Dongdong Zhang, Zhenan Shen, Ke Yang, Jing Chen, Huanhuan Zhao, Xinyue Yang, Li Lu, Huaiwu |
author_sort | Wang, Nannan |
collection | PubMed |
description | Breast cancer and gynecological tumors seriously endanger women’s physical and mental health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and radiotherapy, the prognosis and overall survival of cancer patients have improved compared to earlier, but the management of advanced disease still faces great challenges. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been clinically approved for breast and gynecological cancer patients, significantly improving their quality of life, especially of patients with BRCA1/2 mutations. However, drug resistance faced by PARPi therapy has hindered its clinical promotion. Therefore, developing new drug strategies to resensitize cancers affecting women to PARPi therapy is the direction of our future research. Currently, the effects of PARPi in combination with other drugs to overcome drug resistance are being studied. In this article, we review the mechanisms of PARPi resistance and summarize the current combination of clinical trials that can improve its resistance, with a view to identify the best clinical treatment to save the lives of patients. |
format | Online Article Text |
id | pubmed-9455597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94555972022-09-09 PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies Wang, Nannan Yang, Yan Jin, Dongdong Zhang, Zhenan Shen, Ke Yang, Jing Chen, Huanhuan Zhao, Xinyue Yang, Li Lu, Huaiwu Front Pharmacol Pharmacology Breast cancer and gynecological tumors seriously endanger women’s physical and mental health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and radiotherapy, the prognosis and overall survival of cancer patients have improved compared to earlier, but the management of advanced disease still faces great challenges. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been clinically approved for breast and gynecological cancer patients, significantly improving their quality of life, especially of patients with BRCA1/2 mutations. However, drug resistance faced by PARPi therapy has hindered its clinical promotion. Therefore, developing new drug strategies to resensitize cancers affecting women to PARPi therapy is the direction of our future research. Currently, the effects of PARPi in combination with other drugs to overcome drug resistance are being studied. In this article, we review the mechanisms of PARPi resistance and summarize the current combination of clinical trials that can improve its resistance, with a view to identify the best clinical treatment to save the lives of patients. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9455597/ /pubmed/36091750 http://dx.doi.org/10.3389/fphar.2022.967633 Text en Copyright © 2022 Wang, Yang, Jin, Zhang, Shen, Yang, Chen, Zhao, Yang and Lu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Nannan Yang, Yan Jin, Dongdong Zhang, Zhenan Shen, Ke Yang, Jing Chen, Huanhuan Zhao, Xinyue Yang, Li Lu, Huaiwu PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies |
title | PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies |
title_full | PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies |
title_fullStr | PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies |
title_full_unstemmed | PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies |
title_short | PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies |
title_sort | parp inhibitor resistance in breast and gynecological cancer: resistance mechanisms and combination therapy strategies |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455597/ https://www.ncbi.nlm.nih.gov/pubmed/36091750 http://dx.doi.org/10.3389/fphar.2022.967633 |
work_keys_str_mv | AT wangnannan parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT yangyan parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT jindongdong parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT zhangzhenan parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT shenke parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT yangjing parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT chenhuanhuan parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT zhaoxinyue parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT yangli parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies AT luhuaiwu parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies |